Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that it has submitted a Clinical Trial Application (CTA) in
Gamma Biosciences, a life sciences tools platform created by KKR, has announced a licensing agreement between Astrea Bioseparations, a leader in affinity chromatography and bioseparations, and Avacta, a developer of
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the agreement with Astrea Bioseparations. Alastair explains what affinity separation is, tell us about the market, the details of the
Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that it has entered into a license agreement with Astrea
The finalists in the 2020 Cambridge Independent Science and Technology Awards can now be revealed. Following hundreds of entries, a shortlist across 14 categories has been drawn up. Biotech Company of the
Avacta Group has announced progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the
U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral
Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in
Avacta Group’s Alistair Smith discusses the various covid-19 related tests, the key points from the lateral flow rapid antigen test announcement, progress on other tests, taking the preCISION pro drug into the clinic and what other updates we can expect in the coming months in this exclusive interview with DirectorsTalk.
Yorkshire-based Avacta is in talks to establish the route to market for a COVID-19 test that can be deployed in hospitals in the UK and Europe. Avacta Group has announced
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
